3 December 2021 – Zaiding Pharmaceutical Co., Ltd. (NASDAQ: ZLAB; HKEx Stock Code: 9688), an innovative patient-centered, commercialized global biopharmaceutical company, today announced that Zele (Nilapali) has been included in the latest National Medicare Catalogue of Medicare drugs released by the National Health Insurance Authority of the People's Republic of China for advanced epithelial, fallopian tube or primary peritoneal cancer (collectively, ovarian cancer) First-line maintenance therapy in adults after responding to platinum-containing chemotherapy, regardless of biomarker status.
Dr. Du Ying, Founder, Chairman and CEO of Zaiding Pharmaceutical, said: "Bringing transformative and innovative drugs to Chinese patients is one of our important missions, and the inclusion of Zele ® Frontline Maintenance Treatment for Ovarian Cancer in the National Medical Insurance Drug Catalogue has taken us another step towards this mission. Many thanks to the National Health Insurance Bureau, which will further enhance the accessibility of ovarian cancer patients in China to Zele ®. "
Liang Yi, Chief Commercial Officer of Zaiding Pharmaceutical, said: "National medical insurance reimbursement can improve the accessibility of ovarian cancer patients in China to Zele. Zele ® is the only APPROVED PARP inhibitor that can be used as a single agent for maintenance therapy for first-line and recurrent ovarian cancer, regardless of the patient's biomarker status. The inclusion of Zele ® in the national medical insurance drug list also highlights the clinical value of Zele ® for the majority of ovarian cancer patients. "
In November 2021, Zaiding Pharmaceutical announced that the Phase 3 clinical study PRIME of Zele ® as maintenance therapy had reached the primary study endpoint, confirming that for newly diagnosed patients with advanced ovarian cancer in China, regardless of the biomarker status, lele as a maintenance therapy can achieve significant benefits in progression-free survival (PFS) in both a statistical and clinical sense, and the safety is manageable.
In December 2020, Zele was included in the National Medical Insurance Drug List for maintenance treatment in adult patients with platinum-sensitive recurrent ovarian cancer.
This article originated from Grand Gateway
![096 phase of barrel bone radish soup 097 issue of ingredients details of the method steps of bone radish soup tips[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)